Organogenesis Holdings Inc.
General ticker "ORGO" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $525.4M (TTM average)
Organogenesis Holdings Inc. does not follow the US Stock Market performance with the rate: -0.6%.
Estimated limits based on current volatility of 4.3%: low 2.25$, high 2.45$
Factors to consider:
- Total employees count: 869 (+0.8%) as of 2024
- Top business risk factors: Market competition, Physician support, Supply chain disruptions, Tissue supply risks, Reimbursement risks
- Current price 39.8% below estimated low
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.87$, 7.08$]
- 2026-12-31 to 2027-12-31 estimated range: [3.79$, 6.98$]
Financial Metrics affecting the ORGO estimates:
- Positive: with PPE of 20.3 at the end of fiscal year the price was low
- Negative: negative Operating cash flow
- Positive: 7.54 < Operating profit margin, % of 7.92
- Positive: 1.81 < Return on assets ratio (scaled to [-100,100]) of 5.82
- Positive: 42.59 < Shareholder equity ratio, % of 50.13 <= 64.29
- Positive: -4.41 < Investing cash flow per share per price, % of -2.04
- Positive: Inventory ratio change, % of -0.17 <= 0
- Negative: negative Industry operating cash flow (median)
Short-term ORGO quotes
Long-term ORGO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $433.14MM | $482.04MM | $564.17MM |
| Operating Expenses | $420.62MM | $483.33MM | $519.48MM |
| Operating Income | $12.53MM | $-1.28MM | $44.69MM |
| Non-Operating Income | $-2.13MM | $-1.52MM | $2.28MM |
| Interest Expense | $2.19MM | $1.54MM | $2.28MM |
| R&D Expense | $44.38MM | $50.27MM | $44.54MM |
| Income(Loss) | $10.39MM | $-2.81MM | $46.97MM |
| Taxes | $5.45MM | $-3.67MM | $9.94MM |
| Net Income(Loss)* | $4.95MM | $0.86MM | $37.03MM |
| Stockholders Equity | $278.66MM | $262.90MM | $300.13MM |
| Inventory | $28.25MM | $26.22MM | $29.63MM |
| Assets | $460.02MM | $497.89MM | $598.73MM |
| Operating Cash Flow | $30.92MM | $14.21MM | $-10.31MM |
| Capital expenditure | $24.36MM | $10.03MM | $14.15MM |
| Investing Cash Flow | $-24.36MM | $-10.03MM | $-14.15MM |
| Financing Cash Flow | $-5.50MM | $27.64MM | $-17.36MM |
| Earnings Per Share** | $0.04 | $0.01 | $0.29 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.